<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896801</url>
  </required_header>
  <id_info>
    <org_study_id>PRO7</org_study_id>
    <nct_id>NCT04896801</nct_id>
  </id_info>
  <brief_title>MR-guided Prostate Stereotactic Body Radiotherapy in Seven Days</brief_title>
  <acronym>Proseven</acronym>
  <official_title>Prospective Study of MR-guided Prostate Stereotactic Body Radiotherapy in Seven Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Proseven trial is a prospective interventional study that will evaluate the toxicity and&#xD;
      efficacy of MR-guided stereotactic body radiotherapy (SBRT) in the profound hypofractionated&#xD;
      treatment of prostate cancer. Patients will be treated in 5 daily fractions within a short&#xD;
      overall treatment time (OTT) of 7 days. A simultaneous integrated boost (SIB) will be&#xD;
      delivered to the intraprostatic dominant lesion (if present) in this study. Besides a&#xD;
      potential biological impact of this innovative prostate SBRT treatment, the reduced OTT&#xD;
      offers also benefits in terms of patient convenience. The primary endpoint is clinician&#xD;
      reported grade 2 or more acute gastrointestinal (GI) and genitourinary (GU) toxicity,&#xD;
      assessed using CTCAE v 5.0 and RTOG, measured up to 3 months after the first treatment&#xD;
      fraction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">July 2029</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity according to CTCAE v 5.0</measure>
    <time_frame>from the first treatment fraction up to 3 months</time_frame>
    <description>Clinician reported grade 2 or more acute gastrointestinal (GI) or genitourinary (GU) toxicity, assessed using CTCAE v 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute toxicity according to RTOG criteria</measure>
    <time_frame>from the first treatment fraction up to 3 months</time_frame>
    <description>Clinician reported grade 2 or more acute gastrointestinal (GI) or genitourinary (GU) toxicity, assessed using RTOG criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late toxicity according to CTCAE v 5.0</measure>
    <time_frame>within 5 years after start of radiotherapy</time_frame>
    <description>Clinician reported late toxicity, assessed using CTCAE v 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity according to RTOG criteria</measure>
    <time_frame>within 5 years after start of radiotherapy</time_frame>
    <description>Clinician reported late toxicity, assessed using RTOG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>from the start of radiotherapy until 5 years after treatment</time_frame>
    <description>Quality of life according to EORTC Quality of life Questionnaire C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate specific quality of life assessment</measure>
    <time_frame>from the start of radiotherapy until 5 years after treatment</time_frame>
    <description>Quality of life according to EORTC Quality of life Questionnaire PR25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EPIC-26 quality of life</measure>
    <time_frame>from the start of radiotherapy until 5 years after treatment</time_frame>
    <description>Quality of life according to Expanded Prostate Index Composite-26 (EPIC-26)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS quality of life</measure>
    <time_frame>from the start of radiotherapy until 5 years after treatment</time_frame>
    <description>Quality of life according to International Prostate Symptom Score (IPSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from biochemical failure</measure>
    <time_frame>from start of radiotherapy until PSA relapse, assessed up to 5 years</time_frame>
    <description>the Phoenix definition is used to define PSA failure (i.e. nadir + 2ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>from start of radiotherapy until 5 years after treatment</time_frame>
    <description>from start of radiotherapy until first evidence of recurrence (loco-regional or distant) or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from start of radiotherapy until 5 years after treatment</time_frame>
    <description>from start of radiotherapy until death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>MR-guided prostate stereotactic body radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive MR-guided RT in 5 fractions over 7 days (daily excluding weekend, i.e. start on Wednesday or Thursday, until Tuesday or Wednesday respectively the week after).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MR-guided RT</intervention_name>
    <description>The dose to the planning target volume (PTV) is 36 Gy (5 x 7.2 Gy) prescribed on the 90% isodose line. The clinical target volume (CTV) is receiving 40 Gy (5 x 8 Gy = 100%). A simultaneous integrated boost (SIB) up to a total dose of 42 Gy (5 x 8.4 Gy = 105%) is delivered to the gross tumor volume (GTV), if present. In addition, relative sparing of the urethra will be applied by avoiding hotspots (V40 Gy &lt; 1cc) in the urethra. Baseline and adapted treatment plans are generated using intensity-modulated RT</description>
    <arm_group_label>MR-guided prostate stereotactic body radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 y&#xD;
&#xD;
          -  Histologically confirmed prostate adenocarcinoma&#xD;
&#xD;
          -  Low risk: cT1c-T2a, Gleason score 6, PSA &lt; 10ng/mL&#xD;
&#xD;
          -  Favorable intermediate risk: 1 intermediate risk factor, Gleason 3+4 or less, &lt; 50%&#xD;
             positive biopsy cores)&#xD;
&#xD;
          -  Unfavorable intermediate risk: &gt; 1 intermediate risk factor, Gleason 4+3, &gt; 50%&#xD;
             positive biopsy cores)&#xD;
&#xD;
          -  Limited high risk: cT3a with PSA &lt; 40ng/mL or cT2a-c with a Gleason score &gt; 7 and/or a&#xD;
             PSA &gt; 20ng/mL but &lt; 40ng/mL&#xD;
&#xD;
          -  World Health Organization performance score 0-2&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Intermediate risk factors: T2b-T2c, Gleason 7, PSA 10-20 ng/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Transurethral resection (TUR) &lt; 3months before SBRT&#xD;
&#xD;
          -  International Prostate Symptom Score (IPSS) &gt; 19&#xD;
&#xD;
          -  Prostate volume &gt; 100cc on transrectal ultrasound (TRUS)&#xD;
&#xD;
          -  Stage cT3b-T4&#xD;
&#xD;
          -  N1 disease (clinically or pathologically)&#xD;
&#xD;
          -  M1 disease (clinically or pathologically)&#xD;
&#xD;
          -  PSA &gt; 40ng/mL&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  immunosuppressive medications&#xD;
&#xD;
          -  prior pelvic RT&#xD;
&#xD;
          -  contra-indications for MRI&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedikt Engels, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benedikt Engels, MD</last_name>
    <phone>00324776041</phone>
    <email>benedikt.engels@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark De Ridder, MD</last_name>
    <email>mark.deridder@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedikt Engels, MD</last_name>
      <phone>00324776041</phone>
      <email>benedikt.engels@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Ka Lun Law</last_name>
      <email>ka.lun.law@vub.be</email>
    </contact_backup>
    <investigator>
      <last_name>Benedikt Engels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark De Ridder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Benedikt Engels, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>MR-guided radiotherapy</keyword>
  <keyword>Stereotactic body radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

